These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32944293)

  • 1. Neprilysin as a Biomarker: Challenges and Opportunities.
    Pavo N; Prausmüller S; Bartko PE; Goliasch G; Hülsmann M
    Card Fail Rev; 2020 Mar; 6():e23. PubMed ID: 32944293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation.
    Pavo IJ; Pavo N; Kastner N; Traxler D; Lukovic D; Zlabinger K; Spannbauer A; Riesenhuber M; Lorant D; Bartko PE; Goliasch G; Hülsmann M; Winkler J; Gyöngyösi M
    JACC Basic Transl Sci; 2020 Jul; 5(7):715-726. PubMed ID: 32760858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease.
    Chen Y; Burnett JC
    Clin Chem; 2017 Jan; 63(1):108-115. PubMed ID: 28062615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production of soluble Neprilysin by endothelial cells.
    Kuruppu S; Rajapakse NW; Minond D; Smith AI
    Biochem Biophys Res Commun; 2014 Apr; 446(2):423-7. PubMed ID: 24495806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang.
    Feygina EE; Katrukha AG; Semenov AG
    Biochemistry (Mosc); 2019 Nov; 84(11):1346-1358. PubMed ID: 31760922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism.
    Kjeldsen SAS; Hansen LH; Esser N; Mongovin S; Winther-Sørensen M; Galsgaard KD; Hunt JE; Kissow H; Ceutz FR; Terzic D; Mark PD; Plomgaard P; Goetze JP; Goossens GH; Blaak EE; Deacon CF; Rosenkilde MM; Zraika S; Holst JJ; Wewer Albrechtsen NJ
    J Endocr Soc; 2021 Sep; 5(9):bvab084. PubMed ID: 34337276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-fat hypocaloric diet reduces neprilysin in overweight and obese human subjects.
    Henke C; Haufe S; Ziehl D; Bornstein SR; Schulz-Menger J; Heni M; Engeli S; Jordan J; Birkenfeld AL
    ESC Heart Fail; 2021 Apr; 8(2):938-942. PubMed ID: 33638612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.
    Kawanami T; Karki RG; Cody E; Liu Q; Liang G; Ksander GM; Rigel DF; Schiering N; Gong Y; Coppola GM; Iwaki Y; Sun R; Neubert A; Fan L; Ingles S; D'Arcy A; Villard F; Ramage P; Jeng AY; Leung-Chu J; Liu J; Beil M; Fu F; Chen W; Cumin F; Wiesmann C; Mogi M
    ACS Med Chem Lett; 2020 Feb; 11(2):188-194. PubMed ID: 32071687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
    Januzzi JL; Packer M; Claggett B; Liu J; Shah AM; Zile MR; Pieske B; Voors A; Gandhi PU; Prescott MF; Shi V; Lefkowitz MP; McMurray JJV; Solomon SD
    Circ Heart Fail; 2018 Oct; 11(10):e005133. PubMed ID: 30354399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.
    Katsanos S; Bistola V; Parissis JT
    Expert Rev Clin Pharmacol; 2016 Apr; 9(4):513-523. PubMed ID: 26873036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices.
    de Diego C; González-Torres L; Núñez JM; Centurión Inda R; Martin-Langerwerf DA; Sangio AD; Chochowski P; Casasnovas P; Blazquéz JC; Almendral J
    Heart Rhythm; 2018 Mar; 15(3):395-402. PubMed ID: 29146274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data.
    Cuthbert JJ; Pellicori P; Clark AL
    Ther Clin Risk Manag; 2020; 16():715-726. PubMed ID: 32848403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date.
    Akbar S; Kabra N; Aronow WS
    Ther Clin Risk Manag; 2020; 16():681-688. PubMed ID: 32801725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
    Ayalasomayajula S; Langenickel T; Pal P; Boggarapu S; Sunkara G
    Clin Pharmacokinet; 2018 Jan; 57(1):105-123. PubMed ID: 28527109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
    Prenner SB; Shah SJ; Yancy CW
    Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of neprilysin (EC3.4.24.11) expression in vascular endothelial cells by laminar shear stress involves NADPH oxidase-dependent ROS production.
    Fitzpatrick PA; Guinan AF; Walsh TG; Murphy RP; Killeen MT; Tobin NP; Pierotti AR; Cummins PM
    Int J Biochem Cell Biol; 2009 Nov; 41(11):2287-94. PubMed ID: 19464387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terminating the stress: peripheral peptidolysis of proopiomelanocortin-derived regulatory hormones by the dermal microvascular endothelial cell extracellular peptidases neprilysin and angiotensin-converting enzyme.
    Scholzen TE; König S; Fastrich M; Böhm M; Luger TA
    Endocrinology; 2007 Jun; 148(6):2793-805. PubMed ID: 17363457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions.
    Ambrosy AP; Mentz RJ; Fiuzat M; Cleland JGF; Greene SJ; O'Connor CM; Teerlink JR; Zannad F; Solomon SD
    Eur J Heart Fail; 2018 Jun; 20(6):963-972. PubMed ID: 29464817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.